Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants
Neutralizing antibody-based passive immunotherapy could be an important therapeutic option against COVID-19. Herein, we demonstrate that equines hyper-immunized with chemically inactivated SARS-CoV-2 elicited high antibody titers with a strong virus-neutralizing potential, and F(ab’)2 fragments puri...
Gespeichert in:
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.) Fla.), 2022-04, Vol.237, p.108981-108981, Article 108981 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108981 |
|---|---|
| container_issue | |
| container_start_page | 108981 |
| container_title | Clinical immunology (Orlando, Fla.) |
| container_volume | 237 |
| creator | Gupta, Divya Ahmed, Farhan Tandel, Dixit Parthasarathy, Haripriya Vedagiri, Dhiviya Sah, Vishal Krishna Mohan, B. Khan, Rafiq Ahmad Kondiparthi, Chiranjeevi Savari, Prabhudas Jain, Sandesh Reddy, Shashikala Kumar, Jerald Mahesh Khan, Nooruddin Harshan, Krishnan Harinivas |
| description | Neutralizing antibody-based passive immunotherapy could be an important therapeutic option against COVID-19. Herein, we demonstrate that equines hyper-immunized with chemically inactivated SARS-CoV-2 elicited high antibody titers with a strong virus-neutralizing potential, and F(ab’)2 fragments purified from them displayed strong neutralization potential against five different SARS-CoV-2 variants. F(ab’)2 fragments purified from the plasma of hyperimmunized horses showed high antigen-specific affinity. Experiments in rabbits suggested that the F(ab’)2 displays a linear pharmacokinetics with approximate plasma half-life of 47 h. In vitro microneutralization assays using the purified F(ab’)2 displayed high neutralization titers against five different variants of SARS-CoV-2 including the Delta variant, demonstrating its potential efficacy against the emerging viral variants. In conclusion, this study demonstrates that F(ab’)2 generated against SARS-CoV-2 in equines have high neutralization titers and have broad target-range against the evolving variants, making passive immunotherapy a potential regimen against the existing and evolving SARS-CoV-2 variants in combating COVID-19. |
| doi_str_mv | 10.1016/j.clim.2022.108981 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8926440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521661622000626</els_id><sourcerecordid>35306171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c385t-700f2aaceb59157ba9369bd809d1bbf6e3188664656bdfad37f6ea7f90e743273</originalsourceid><addsrcrecordid>eNp9UU2L1EAQbURx19U_4EH6qIeM_THpJCDCMuyqsCC46rWp7nQyNXQ6sTsZGE_-Df-ev8QeZl304qmKqnqv6tUj5DlnK864er1bWY_DSjAhcqFuav6AnPNS8KJisnx4lyvF1Rl5ktKOMVYKoR6TM1lKpnjFz0m6-rZgcBSHYQlj70ezeAy0i9APLsz0-iWYXz9-vhK0xTR5OCS6xX5Lg1vmCB6_Y-iphQkMepwPFHrAkGY6LH7GyTt6e_npttiMXwtB9xARwpyekkcd-OSe3cUL8uX66vPmfXHz8d2HzeVNYWVdzlkE6wSAdaZseFkZaKRqTFuzpuXGdMpJXtdKrVWpTNtBK6tcg6prmKvWUlTygrw98U6LGVxrs558sp4iDhAPegTU_3YCbnU_7nXdCLVes0wgTgQ2jilF191jOdNHC_ROHy3QRwv0yYIMevH31nvIn5_ngTenAZe179FFnSy6YF2L0dlZtyP-j_83cLCbtQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Gupta, Divya ; Ahmed, Farhan ; Tandel, Dixit ; Parthasarathy, Haripriya ; Vedagiri, Dhiviya ; Sah, Vishal ; Krishna Mohan, B. ; Khan, Rafiq Ahmad ; Kondiparthi, Chiranjeevi ; Savari, Prabhudas ; Jain, Sandesh ; Reddy, Shashikala ; Kumar, Jerald Mahesh ; Khan, Nooruddin ; Harshan, Krishnan Harinivas</creator><creatorcontrib>Gupta, Divya ; Ahmed, Farhan ; Tandel, Dixit ; Parthasarathy, Haripriya ; Vedagiri, Dhiviya ; Sah, Vishal ; Krishna Mohan, B. ; Khan, Rafiq Ahmad ; Kondiparthi, Chiranjeevi ; Savari, Prabhudas ; Jain, Sandesh ; Reddy, Shashikala ; Kumar, Jerald Mahesh ; Khan, Nooruddin ; Harshan, Krishnan Harinivas</creatorcontrib><description>Neutralizing antibody-based passive immunotherapy could be an important therapeutic option against COVID-19. Herein, we demonstrate that equines hyper-immunized with chemically inactivated SARS-CoV-2 elicited high antibody titers with a strong virus-neutralizing potential, and F(ab’)2 fragments purified from them displayed strong neutralization potential against five different SARS-CoV-2 variants. F(ab’)2 fragments purified from the plasma of hyperimmunized horses showed high antigen-specific affinity. Experiments in rabbits suggested that the F(ab’)2 displays a linear pharmacokinetics with approximate plasma half-life of 47 h. In vitro microneutralization assays using the purified F(ab’)2 displayed high neutralization titers against five different variants of SARS-CoV-2 including the Delta variant, demonstrating its potential efficacy against the emerging viral variants. In conclusion, this study demonstrates that F(ab’)2 generated against SARS-CoV-2 in equines have high neutralization titers and have broad target-range against the evolving variants, making passive immunotherapy a potential regimen against the existing and evolving SARS-CoV-2 variants in combating COVID-19.</description><identifier>ISSN: 1521-6616</identifier><identifier>EISSN: 1521-7035</identifier><identifier>DOI: 10.1016/j.clim.2022.108981</identifier><identifier>PMID: 35306171</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; Antisera ; COVID-19 ; COVID-19 - therapy ; F(ab’)2 ; Horses ; Humans ; Immunoglobulin Fab Fragments ; Immunoglobulin Fragments ; Passive immunotherapy ; Rabbits ; SARS-CoV-2 ; Virus neutralization</subject><ispartof>Clinical immunology (Orlando, Fla.), 2022-04, Vol.237, p.108981-108981, Article 108981</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><rights>2022 Elsevier Inc. All rights reserved. 2022 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c385t-700f2aaceb59157ba9369bd809d1bbf6e3188664656bdfad37f6ea7f90e743273</citedby><cites>FETCH-LOGICAL-c385t-700f2aaceb59157ba9369bd809d1bbf6e3188664656bdfad37f6ea7f90e743273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clim.2022.108981$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35306171$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Divya</creatorcontrib><creatorcontrib>Ahmed, Farhan</creatorcontrib><creatorcontrib>Tandel, Dixit</creatorcontrib><creatorcontrib>Parthasarathy, Haripriya</creatorcontrib><creatorcontrib>Vedagiri, Dhiviya</creatorcontrib><creatorcontrib>Sah, Vishal</creatorcontrib><creatorcontrib>Krishna Mohan, B.</creatorcontrib><creatorcontrib>Khan, Rafiq Ahmad</creatorcontrib><creatorcontrib>Kondiparthi, Chiranjeevi</creatorcontrib><creatorcontrib>Savari, Prabhudas</creatorcontrib><creatorcontrib>Jain, Sandesh</creatorcontrib><creatorcontrib>Reddy, Shashikala</creatorcontrib><creatorcontrib>Kumar, Jerald Mahesh</creatorcontrib><creatorcontrib>Khan, Nooruddin</creatorcontrib><creatorcontrib>Harshan, Krishnan Harinivas</creatorcontrib><title>Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants</title><title>Clinical immunology (Orlando, Fla.)</title><addtitle>Clin Immunol</addtitle><description>Neutralizing antibody-based passive immunotherapy could be an important therapeutic option against COVID-19. Herein, we demonstrate that equines hyper-immunized with chemically inactivated SARS-CoV-2 elicited high antibody titers with a strong virus-neutralizing potential, and F(ab’)2 fragments purified from them displayed strong neutralization potential against five different SARS-CoV-2 variants. F(ab’)2 fragments purified from the plasma of hyperimmunized horses showed high antigen-specific affinity. Experiments in rabbits suggested that the F(ab’)2 displays a linear pharmacokinetics with approximate plasma half-life of 47 h. In vitro microneutralization assays using the purified F(ab’)2 displayed high neutralization titers against five different variants of SARS-CoV-2 including the Delta variant, demonstrating its potential efficacy against the emerging viral variants. In conclusion, this study demonstrates that F(ab’)2 generated against SARS-CoV-2 in equines have high neutralization titers and have broad target-range against the evolving variants, making passive immunotherapy a potential regimen against the existing and evolving SARS-CoV-2 variants in combating COVID-19.</description><subject>Animals</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Antisera</subject><subject>COVID-19</subject><subject>COVID-19 - therapy</subject><subject>F(ab’)2</subject><subject>Horses</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments</subject><subject>Immunoglobulin Fragments</subject><subject>Passive immunotherapy</subject><subject>Rabbits</subject><subject>SARS-CoV-2</subject><subject>Virus neutralization</subject><issn>1521-6616</issn><issn>1521-7035</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU2L1EAQbURx19U_4EH6qIeM_THpJCDCMuyqsCC46rWp7nQyNXQ6sTsZGE_-Df-ev8QeZl304qmKqnqv6tUj5DlnK864er1bWY_DSjAhcqFuav6AnPNS8KJisnx4lyvF1Rl5ktKOMVYKoR6TM1lKpnjFz0m6-rZgcBSHYQlj70ezeAy0i9APLsz0-iWYXz9-vhK0xTR5OCS6xX5Lg1vmCB6_Y-iphQkMepwPFHrAkGY6LH7GyTt6e_npttiMXwtB9xARwpyekkcd-OSe3cUL8uX66vPmfXHz8d2HzeVNYWVdzlkE6wSAdaZseFkZaKRqTFuzpuXGdMpJXtdKrVWpTNtBK6tcg6prmKvWUlTygrw98U6LGVxrs558sp4iDhAPegTU_3YCbnU_7nXdCLVes0wgTgQ2jilF191jOdNHC_ROHy3QRwv0yYIMevH31nvIn5_ngTenAZe179FFnSy6YF2L0dlZtyP-j_83cLCbtQ</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Gupta, Divya</creator><creator>Ahmed, Farhan</creator><creator>Tandel, Dixit</creator><creator>Parthasarathy, Haripriya</creator><creator>Vedagiri, Dhiviya</creator><creator>Sah, Vishal</creator><creator>Krishna Mohan, B.</creator><creator>Khan, Rafiq Ahmad</creator><creator>Kondiparthi, Chiranjeevi</creator><creator>Savari, Prabhudas</creator><creator>Jain, Sandesh</creator><creator>Reddy, Shashikala</creator><creator>Kumar, Jerald Mahesh</creator><creator>Khan, Nooruddin</creator><creator>Harshan, Krishnan Harinivas</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20220401</creationdate><title>Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants</title><author>Gupta, Divya ; Ahmed, Farhan ; Tandel, Dixit ; Parthasarathy, Haripriya ; Vedagiri, Dhiviya ; Sah, Vishal ; Krishna Mohan, B. ; Khan, Rafiq Ahmad ; Kondiparthi, Chiranjeevi ; Savari, Prabhudas ; Jain, Sandesh ; Reddy, Shashikala ; Kumar, Jerald Mahesh ; Khan, Nooruddin ; Harshan, Krishnan Harinivas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c385t-700f2aaceb59157ba9369bd809d1bbf6e3188664656bdfad37f6ea7f90e743273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Antisera</topic><topic>COVID-19</topic><topic>COVID-19 - therapy</topic><topic>F(ab’)2</topic><topic>Horses</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments</topic><topic>Immunoglobulin Fragments</topic><topic>Passive immunotherapy</topic><topic>Rabbits</topic><topic>SARS-CoV-2</topic><topic>Virus neutralization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Divya</creatorcontrib><creatorcontrib>Ahmed, Farhan</creatorcontrib><creatorcontrib>Tandel, Dixit</creatorcontrib><creatorcontrib>Parthasarathy, Haripriya</creatorcontrib><creatorcontrib>Vedagiri, Dhiviya</creatorcontrib><creatorcontrib>Sah, Vishal</creatorcontrib><creatorcontrib>Krishna Mohan, B.</creatorcontrib><creatorcontrib>Khan, Rafiq Ahmad</creatorcontrib><creatorcontrib>Kondiparthi, Chiranjeevi</creatorcontrib><creatorcontrib>Savari, Prabhudas</creatorcontrib><creatorcontrib>Jain, Sandesh</creatorcontrib><creatorcontrib>Reddy, Shashikala</creatorcontrib><creatorcontrib>Kumar, Jerald Mahesh</creatorcontrib><creatorcontrib>Khan, Nooruddin</creatorcontrib><creatorcontrib>Harshan, Krishnan Harinivas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical immunology (Orlando, Fla.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Divya</au><au>Ahmed, Farhan</au><au>Tandel, Dixit</au><au>Parthasarathy, Haripriya</au><au>Vedagiri, Dhiviya</au><au>Sah, Vishal</au><au>Krishna Mohan, B.</au><au>Khan, Rafiq Ahmad</au><au>Kondiparthi, Chiranjeevi</au><au>Savari, Prabhudas</au><au>Jain, Sandesh</au><au>Reddy, Shashikala</au><au>Kumar, Jerald Mahesh</au><au>Khan, Nooruddin</au><au>Harshan, Krishnan Harinivas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants</atitle><jtitle>Clinical immunology (Orlando, Fla.)</jtitle><addtitle>Clin Immunol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>237</volume><spage>108981</spage><epage>108981</epage><pages>108981-108981</pages><artnum>108981</artnum><issn>1521-6616</issn><eissn>1521-7035</eissn><abstract>Neutralizing antibody-based passive immunotherapy could be an important therapeutic option against COVID-19. Herein, we demonstrate that equines hyper-immunized with chemically inactivated SARS-CoV-2 elicited high antibody titers with a strong virus-neutralizing potential, and F(ab’)2 fragments purified from them displayed strong neutralization potential against five different SARS-CoV-2 variants. F(ab’)2 fragments purified from the plasma of hyperimmunized horses showed high antigen-specific affinity. Experiments in rabbits suggested that the F(ab’)2 displays a linear pharmacokinetics with approximate plasma half-life of 47 h. In vitro microneutralization assays using the purified F(ab’)2 displayed high neutralization titers against five different variants of SARS-CoV-2 including the Delta variant, demonstrating its potential efficacy against the emerging viral variants. In conclusion, this study demonstrates that F(ab’)2 generated against SARS-CoV-2 in equines have high neutralization titers and have broad target-range against the evolving variants, making passive immunotherapy a potential regimen against the existing and evolving SARS-CoV-2 variants in combating COVID-19.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35306171</pmid><doi>10.1016/j.clim.2022.108981</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6616 |
| ispartof | Clinical immunology (Orlando, Fla.), 2022-04, Vol.237, p.108981-108981, Article 108981 |
| issn | 1521-6616 1521-7035 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8926440 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Antibodies, Neutralizing Antibodies, Viral Antisera COVID-19 COVID-19 - therapy F(ab’)2 Horses Humans Immunoglobulin Fab Fragments Immunoglobulin Fragments Passive immunotherapy Rabbits SARS-CoV-2 Virus neutralization |
| title | Equine immunoglobulin fragment F(ab’)2 displays high neutralizing capability against multiple SARS-CoV-2 variants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T11%3A52%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Equine%20immunoglobulin%20fragment%20F(ab%E2%80%99)2%20displays%20high%20neutralizing%20capability%20against%20multiple%20SARS-CoV-2%20variants&rft.jtitle=Clinical%20immunology%20(Orlando,%20Fla.)&rft.au=Gupta,%20Divya&rft.date=2022-04-01&rft.volume=237&rft.spage=108981&rft.epage=108981&rft.pages=108981-108981&rft.artnum=108981&rft.issn=1521-6616&rft.eissn=1521-7035&rft_id=info:doi/10.1016/j.clim.2022.108981&rft_dat=%3Cpubmed_cross%3E35306171%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35306171&rft_els_id=S1521661622000626&rfr_iscdi=true |